Clinical Trial Update: Zoledronic Acid for the Prevention of Bone Loss Post-bone Marrow Transplantation for Thalassemia Major Patients [Phase 2, Phase 3]

View source ↗

Summary

A Phase 2/3 clinical trial evaluates zoledronic acid to prevent bone loss after bone marrow transplantation in patients with beta-thalassemia major; current sta…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Beta Thalassemia Major

Drugs mentioned

• Zoledronic acid (Zoledronic acid)

Snippet

Sponsor: Tehran University of Medical Sciences | Conditions: Beta-Thalassemia, Bone Marrow Transplantation | Phase 2, Phase 3 | Status: UNKNOWN